<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Clinical features of 40 lymphoproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> patients in the setting of systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> managed in the Clinic of Hematology during 1994-2006 were analyzed retrospectively </plain></SENT>
<SENT sid="1" pm="."><plain>The classification of systemic <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> patients was as follows: 15 <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>--SLE, 11 <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>--RA, 12 Sj√∂gren's syndrome--SS, 1 <z:hpo ids='HP_0100324'>scleroderma</z:hpo>, and 1 dermatomyositis </plain></SENT>
<SENT sid="2" pm="."><plain>Patients comprised 31 women and 9 men of mean age 55 years (range 33-76) </plain></SENT>
<SENT sid="3" pm="."><plain>Systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> preceeded the development of lymphoproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> in 37/40 (92.5%) patients </plain></SENT>
<SENT sid="4" pm="."><plain>Mean latency period between the <z:hpo ids='HP_0003674'>onset</z:hpo> of systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and lymphoproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> occurrence was significantly longer in RA (113 months) than in SLE (75 months) and SS patients (65 months)--P &lt; 0.05 </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequent lymphoproliferative <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>--NHL (35/40; 88%), diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (DBCL)--12 (34%), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FC)--7 (20%), small lymphocytic (SL), and marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>)--5 (14%) each </plain></SENT>
<SENT sid="6" pm="."><plain>The primary site of NHL was extranodal in 18/35 (51.5%) cases </plain></SENT>
<SENT sid="7" pm="."><plain>Advanced disease on diagnosis (III + IV clinical stages), constitutional symptoms, and bulky disease were diagnosed in 27/35 (77%), 26/35 (74%), and 3/35 (8.5%) patients, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The overall survival (OS) was as follows (months): DBCL-12, FC-63, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>-60, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MZL</z:e>-48 </plain></SENT>
<SENT sid="9" pm="."><plain>There was no association between the lymphoproliferative <z:hpo ids='HP_0002664'>neoplasm</z:hpo> histological subtype and the systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> type or antirheumatic treatment P &gt; 0.05 </plain></SENT>
<SENT sid="10" pm="."><plain>Our findings are in line with earlier reports showing a high proportion of patients with advanced disease, constitutional symptoms, extranodal manifestations, high grade histology, and low OS in the systemic <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> setting </plain></SENT>
</text></document>